

1

2 A RT-qPCR system using a degenerate probe for specific identification and
3 differentiation of SARS-CoV-2 Omicron (B.1.1.529) Variants of Concern

4

5

6 Randi Jessen¹, Line Nielsen¹, Nicolai Balle Larsen¹, Arieh Sierra Cohen¹, Vithiagarun Gunalan²,
7 Ellinor Marving², Alonzo Alfaro-Núñez³, Charlotta Polacek², The Danish COVID-19 Genome
8 Consortium (DCGC)⁴, Anders Fomsgaard², Katja Spiess^{2*}

9

10

11

12

13

14

15 ¹Test Center Denmark, Statens Serum Institut, Denmark

16

17 ²Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Denmark

18

19 ³Department of Clinical Biochemistry, Naestved Hospital, Denmark

20

21 ⁴ <https://www.covid19genomics.dk>

22

23

24 *Corresponding author:

25 Email: ktsp@ssi.dk (Katja Spiess, KS)

26

27 **Abstract**

28 Fast surveillance strategies are needed to control the spread of new emerging SARS-CoV-2 variants
29 and gain time for evaluation of their pathological potential. This was essential for the Omicron variant
30 (B.1.1.529) that replaced the Delta variant (B.1.617.2) and is currently the dominant SARS-CoV-2
31 variant circulating worldwide. RT-qPCR strategies complement whole genome sequencing,
32 especially in resource lean countries, but mutations in the targeting primer and probe sequences of
33 new emerging variants can lead to a failure of the existing RT-qPCRs. Here, we introduced an RT-
34 qPCR platform for detecting the Delta- and the Omicron variant simultaneously using a degenerate
35 probe targeting the key $\Delta H69/V70$ mutation in the spike protein. By inclusion of the L452R mutation
36 into the RT-qPCR platform, we could detect not only the Delta and the Omicron variants, but also
37 the Omicron sub-lineages BA.1, BA.2 and BA.4/BA.5. The RT-qPCR platform was validated in
38 small- and large-scale. It can easily be incorporated for continued monitoring of Omicron sub-
39 lineages, and offers a fast adaption strategy of existing RT-qPCRs to detect new emerging SARS-
40 CoV-2 variants using degenerate probes.

41 **Keywords**

42 SARS-CoV-2, Omicron, B.1.1.529, RT-qPCR, Variant-PCR, degenerate probe, SARS-CoV-2
43 variants.

44

45 **Introduction**

46 The World Health Organization designated the SARS-CoV-2 variant B.1.1.529 as a variant of
47 concern (VOC) with the name ‘Omicron’ on November 26th, 2021(1). Omicron, first identified in
48 South Africa and Botswana in November 2021, has spread rapidly worldwide and is the current
49 dominant strain in at least 166 nations worldwide, replacing the Delta variant(2). Since its designation
50 as a VOC, Omicron has continued to evolve, leading to descendent lineages, termed BA.1-5, with
51 different genetic constellations of mutations (1).

52 The Omicron variant is exceptional for carrying a large number of mutations not seen in combination
53 before, including more than 40 mutations in the spike protein (3,4). The spike protein is the main
54 target of antibodies generated by infection and of many vaccines widely administered, and these
55 mutations are therefore associated with increased transmissibility (5) and immune escape (6,7).

56 Initially, the BA.1 sub-variant was the dominant circulating version of Omicron. However, since the
57 beginning of 2022, the proportion of BA.2 sampled by whole genome sequencing (WGS) has
58 increased dramatically, making BA.2 the dominant SARS-CoV-2 virus globally (2). BA.1 and BA.2
59 differ by 19 signature mutations located in the N-terminal and in the receptor-binding domain (RBD)
60 of the spike gene, which makes them as different as some other major variants, *e.g.* the diversity
61 between the original Wuhan and the Alpha variant in the spike gene is less than between BA.1 and
62 BA.2 (3,4). One notable difference between BA.1 and BA.2 is that BA.2 lacks the characteristic S-
63 gene target failure (SGTF)-causing deletion, Δ H69/V70. This key mutation, a 2-amino acid deletion,
64 has appeared in multiple SARS-CoV-2 variants, including the Alpha variant (B.1.1.7) (8). BA.4 and
65 BA.5 have an identical BA.2-like constellation of mutations in the spike protein, but carry additional
66 signature mutations including S: Δ H69/V70 and S: L452R. The differences between BA.4 and BA.5

67 instead lie outside the spike gene. The first cases of BA.4 and BA.5 were reported from the Republic
68 of South Africa in January 2022 (2) and subsequently have been found in at least 60 countries (2). In
69 Denmark, 1,091 patient samples infected with BA.4 and 6,685 infected with BA.5 have been
70 confirmed by whole genome sequencing (WGS) per 22nd of June, 2022 (9). BA.4 and BA.5 display
71 higher transmission than other Omicron sub-variants and evade immunity from natural infections or
72 vaccines to a higher extent than BA.1 and BA.2, although not completely, enabling BA.4 and BA.5
73 to infect people who were immune to prior sub-lineages of Omicron and other variants (10). As
74 Omicron continuously evolves under immune pressure, it may develop mutations that would
75 undermine most broadly-neutralizing therapeutic antibodies.

76 Denmark has one of the highest SARS-CoV-2 Reverse Transcription Real-time PCR (RT-qPCR)
77 testing and WGS capacities in the world (11). As part of this, a flexible RT-qPCR platform termed
78 Variant-PCR was developed for identification and monitoring of circulating SARS-CoV-2 variants
79 of concern (VOCs) in near real-time, enabling rapid decision-making about testing, contact tracking
80 and isolation (12). The Variant-PCR platform utilizes signature mutations or combinations hereof
81 that allow differentiation of the most critical VOCs by detection of four signature mutations in the
82 SARS-CoV-2 spike protein: Δ H69/V70, L452R, E484K and N501Y (12).

83 We designed a degenerate probe for the detection of the Δ H69/V70 key mutation in both Alpha and
84 Omicron variants. By including additional results from L452R RT-qPCR, we were able to distinguish
85 between the BA.1 and BA.2 sub-lineages, the Delta variant, and furthermore detect BA.4 and BA.5
86 as they emerged, although differentiation between BA.4 and BA.5 was not possible as they share the
87 same spike protein mutations. Although BA.4 emerged before BA.5 in Denmark, BA.5 is now the
88 dominant SARS-CoV-2 variant (9). Validation was performed in small-scale and performance was

89 confirmed in large-scale diagnostic settings after adaptation of the Variant-PCR to include the
90 degenerate Δ H69V/70 probe, using paired WGS consensus genomes.

91 This study proves that a flexible platform such as the Variant-PCR platform can be adapted quickly
92 and easily with a degenerate probe to monitor and differentiate existing and upcoming SARS-CoV-2
93 variants as part of a national testing program to help policy-makers to make public health decisions.

94 **Materials and methods**

95 **Ethics**

96 Exemption for review by the ethical committee system and informed consent was given by the
97 Committee on Biomedical Research Ethics – Capital region in accordance with Danish law on assay
98 development projects.

99 **Samples and controls**

100 TWIST Synthetic SARS-CoV-2 RNA control (MT103907 England/205041766/2020) were
101 purchased from TWIST bioscience in a known concentration (approx. 1.000.000 copies/ μ l) and used
102 as PCR standard Alpha (B.1.17) in 1:10 dilution series. The average Ct-values and standard deviations
103 were calculated based on biological duplicates.

104 Patient samples infected with SARS-CoV-2 WT, Alpha variant B.1.1.7, Delta variant B.1.617.2 and
105 Omicron variant B.1.529 were obtained from the Danish National Biobank to verify whether the RT-
106 qPCR assays performs with all circulating VOCs (20). In short, throat swabs were collected and tested
107 SARS-CoV-2 positive from community testing facilities (Test Center Denmark), which form part of

108 the Danish national testing program (11). Primary diagnosis of SARS-CoV-2 infection was made by
109 E-Sarbeco RT-qPCR (13).

110 Positive controls for large-scale RT-qPCR consisted of three heat-activated (56°C for 45 minutes)
111 Danish virus isolates covering four key mutations present in the Alpha variant B.1.1.7 (E12), Delta
112 variant B.1.617.2 (H12) and Beta variant B.1.351 (F12). Virus isolation and cultivation was
113 performed as previously described (12). Sterile 1x PBS pH 7.2 (Gibco) was used as negative controls.
114 Positive and negative controls were run in parallel with selected clinical samples throughout RNA
115 isolation and RT-qPCR as described before (12).

116 **RNA extraction**

117 For small-scale experiments, viral genomes from throat swabs collected in 1xPBS (200 µL) were
118 isolated using MagNa Pure 96 nucleic acid extraction system (Roche) with reagents from the MagNa
119 Pure 96 DNA and Viral NA Small Volume kit with 200 µL sample in 1xPBS as input and 100 µL
120 elution. As positive control material, supernatant from SARS-CoV-2 infected cells (120 µL) were
121 mixed with 120 µL of MagNA Pure Lysis Buffer (Roche) followed by extraction as small-scale
122 SARS-CoV-2 patient samples. Positive control RNA was stored at -80°C until use. For large-scale
123 SARS-CoV-2 patient screening (Variant-PCR), viral RNA was extracted using Beckman Coulter
124 RNAdvance Viral Reagent kit with 200 µl sample in 1xPBS as input and 50 µl Nuclease-free water
125 for elution on Beckman Coulter Biomek i7 automated workstations.

126 **RT-qPCR assays**

127 The sequences of the primers and probes listed in Table 1 were synthesized and HPLC-purified by
128 Biosearch Technologies, Denmark. To perform allelic discrimination analysis, two probes were

129 designed for each key mutation in the spike gene: one detecting the wildtype nucleotide sequence and
130 one detecting the mutation, based on sequence alignments using Geneious Prime 2021.0 (12). The
131 assay targeting the E gene (E-Sarbeco) was used as unspecific control to determine the presence of
132 the SARS-CoV-2 and estimate the viral load (13).

133 The reaction mixtures for the RT-qPCR experiments were prepared as follows:

134 For each 25 μ L reaction in 96-well format used in small-scale experiment, 5 μ L extracted RNA were
135 added to 20 μ L reaction mix containing 12.5 μ L Luna® Universal Probe One-step RT-qPCR reaction
136 buffer (New England Biolabs Inc), 1.25 μ L Luna® Warmstart RT Enzyme mix, primers and probes
137 (100 μ M, see volumes in Table 1) and nuclease-free water.

138 For each 15 μ L reaction in 384-well format used for large-scale screening, 5 μ L extracted RNA were
139 added to 10 μ L reaction mix containing 7.5 μ L Luna® Universal Probe One-step RT-qPCR reaction
140 buffer (New England Biolabs Inc), 0.75 μ L Luna® Warmstart RT Enzyme mix, primers and probes
141 (100 μ M, see volumes in Table 1) and nuclease-free water. The setup in 384-well mastermix plates
142 were arranged in a quadratic pattern enabling analysis of each patient sample with four different
143 mastermixes in parallel, using first quadrante to detect Δ 69/70, the second to detect L452R, the third
144 to detect E-Sarbeco and the final well was not in use (water). This allowed for easy transfer of purified
145 RNA from a 96-well format used during extraction to a 384-well mastermix plate for PCR (*e.g.*
146 isolated RNA in A1 in the 96-well template plate was transferred to A1, A2, B1 and B2 of the
147 mastermix plate).

148 The PCR program consists of reverse transcription at 55°C for 10 min., initial denaturation at 95°C
149 for 3 min., followed by 45 cycles of denaturation and annealing/extension at 95°C for 15 sec., and
150 58°C for 30 sec., respectively, regardless of PCR plate format.

151 All RT-qPCR reactions were performed in a calibrated Bio-Rad CFX real-time PCR instrument. The
 152 raw data was analysed with the Bio-Rad CFX Maestro Software using a predefined threshold cut-off
 153 value of 100 RFU as a quality step, in case one of the probes in the allelic discrimination pair failed.
 154 Recorded Ct-values and end-RFU were calculated in Maestro version 5.2.8.222 and exported for
 155 further data analysis. For the mutations Δ H69/V70 and L452R, detection was based on allelic
 156 discrimination where the end-RFU values were utilized to determine the presence of a mutation. A
 157 sample is considered positive based on the following criteria: Ct-values between 10-38 and end-RFU
 158 > 200 at Ct = 45.

159 **Table 1. Primers and probe sequences and relative concentration used in RT-qPCRs.**

Target	Name	Oligo	Volume (μ L)	Ref
S: Δ 69/70	SARS-CoV-2_ Δ 69/70 F	ACATTCAACTCAGGACTTGTCT	0.1	(12)
	SARS-CoV-2_ Δ 69/70 R	TCATTAAATGGTAGGACAGGGTT	0.1	(12)
	SARS-CoV-2_ Δ 69/70 P	HEX-TTCCATGCTATCTCTGGGACCA-BHQ2	0.05	(12)
	SARS-CoV-2_ Δ 69/70 P_Wob	HEX-TTCCATG Y TATCTCTGGGACCA-BHQ1	0.05	
	SARS_CoV-2_WT_P3	Texas Red-TACATGTCTCTGGGACCAAT-BHQ2	0.05	(12)
S: L452R	SARS-CoV-2_L452R F	CAGGCTGCGTTATAGCTTGGA	0.1	(12)
	SARS-CoV-2_L452R R	CCGGCCTGATAGATTTCAGT	0.1	(12)
	SARS-CoV-2_452R_mutant_BHQ+ P	HEX-TATAATTAC C GGTATAGATTGTT-BHQ1	0.05	(12)
	SARS-CoV-2_L452_WT BHQ+ P	Cal Fluor Red 610-TATAATTAC T GTATAGATTGTT-BHQ1	0.05	(12)
E-gene	E_Sarbeco_F	ACAGGTACGTTAATAGTTAATAGCGT	0.1	(12)
	E_Sarbeco_R	ATATTGCAGCAGTACGCACACA	0.1	(12)
	E_Sarbeco_P1	FAM-ACACTAGCCATCCTTACTGCGCTTCG-BHQ1	0.05	(12)

160 Mutation specific nucleotides are highlighted in bold.

161 Whole Genome Sequencing

162 Identities of mutation signatures were confirmed by Whole genome sequences generated by The
163 Danish COVID-19 Genome Consortium (DCGC) from PCR-positive samples as described by (12).

164 **Results**

165 **A degenerate Δ H69/V70 probe is specific for Omicron detection**

166 We evaluated the analytical performance characteristics of the Δ H69/V70 RT-qPCR included in our
167 Variant-PCR for the qualitative detection of Omicron in clinical samples. First, SARS-CoV-2 positive
168 clinical samples containing Omicron (B.1.529), Alpha (B.1.1.7) as positive control, as well as Wuhan
169 (SARS-CoV-2 WT), Delta (B.1.617.2) and negative SARS-CoV-2 patient samples as negative
170 controls, were included into the Δ H69/V70 RT-qPCR (Fig 1A). The presence of SARS-CoV-2 was
171 confirmed in positive samples by E-Sarbeco RT-qPCR (13) multiplexed with the Δ H69/V70 RT-
172 qPCR (Fig 1B).

173 The original Δ H69/V70 RT-qPCR (probe design based on the SARS-CoV-2 alpha variant sequence)
174 was able to detect the Δ H69/V70 mutation in Omicron confirmed samples (Fig 1A). However, the
175 end fluorescence intensity was reduced about five times in Omicron BA.1 (265 RFU) compared to
176 samples with SARS-CoV-2 Alpha (1407 RFU). Sequence analysis revealed a single nucleotide
177 substitution from C-to-T at nucleotide position 21696 in the Omicron BA.1 sequence, resulting in a
178 mismatch in the middle of Δ H69/V70 probe binding region, which led to the observed reduction of
179 the fluorescence intensity.

180 In order to detect the Δ H69/V70 mutation in all known SARS-CoV-2 variants, we designed a
181 degenerate Δ H69/V70 probe (Fig 2). Replacing the original probe targeting Δ H69/V70 with the
182 degenerate probe led to almost a full recovery of the end fluorescence intensity (Fig 2A) in both

183 SARS-CoV-2 variants (Alpha and Omicron) (Fig 2A). Specificity of the degenerate probe was
184 confirmed by the lack of signal from SARS-CoV-2 variants lacking the H69/V70 deletion (SARS-
185 CoV-2 WT, Delta, Omicron BA.2), as well as for the negative controls (Fig2A). In order to
186 discriminate between BA.1 and BA.2 sub-variants, we included a WT probe in the Δ H69/V70 RT-
187 qPCR. All SARS-CoV-2 variants lacking the Δ H69/V70 (SARS-CoV-2 WT, Delta, Omicron BA.2)
188 were detected correctly by the H69/V70 WT probe (Fig 2B). Moreover, the fluorescence intensity
189 was slightly reduced for the degenerate probe compared to the original probe targeting the Δ H69/V70
190 present in the SARS-CoV-2 Alpha variant (synthesized standard TWIST control) (Suppl, Fig1), but
191 the sensitivity was not reduced, as judged by dilutions of a commercial standard (Tab.1; Suppl, Fig1).

192 **Table 1. Threshold values (Ct) reported for the TWIST Synthetic SARS-CoV-2 RNA Quality Control**
193 **samples tested by the original and degenerate Δ H69/70 probe in RT-qPCR.**

SARS-CoV-2 lineage	Concentration	Original Δ H69/V70 probe (Ct value \pm s.d.)	Degenerate Δ H69/V70 probe (Ct value \pm s.d.)
Alpha B.1.17	1 x 10 ⁻³	27.5 \pm 0.2	27.6 \pm 0.6
Alpha B.1.17	1 x 10 ⁻⁴	31.2 \pm 0.3	31.7 \pm 0.2
Alpha B.1.17	1 x 10 ⁻⁵	34.4 \pm 0.4	35.4 \pm 0.007
Alpha B.1.17	1 x 10 ⁻⁶	37.2 \pm 0.4	38.3 \pm 0.08
Alpha B.1.17	1 x 10 ⁻⁷	>45	> 38.6
NTC	0	>45	>45

194 Values reported with a standard deviation are average of duplicates. Threshold values reported as "> 45" indicate that the target is not
195 detected, values reported as ">" gives the lowest Ct values measured with some replicates > 45. NTC: no template control.

196

197 **Large-scale performance confirmation of allelic discrimination RT-**
198 **qPCR with degenerate Δ H69/V70 probe**

199 The Δ H69/V70-WT RT-qPCR with the degenerate probe was validated on 745 PCR-positive SARS-
200 CoV-2 patient samples collected from 3rd to 16th of January 2022 as part of the Danish national testing
201 program. This period was selected since Omicron BA.1 and BA.2 sub-lineages were present in
202 approximately equal proportions (9).

203 The H69/V70 deletion is not present in the SARS-CoV-2 variants Delta and Omicron BA.2; therefore
204 the L452R RT-qPCR was included into the RT-qPCR large-scale screening platform (12,14).
205 Running two RT-qPCRs, each directed against one specific key mutation, *e.g.* Δ H69/V70 and L452R,
206 made it possible to detect four different variants (Table 2).

207 **Table 2. SARS-CoV-2 variants and sub-lineages detected by the combination of Δ H69/V70 and L452R**
208 **RT-qPCRs.**

H69/V70 RT-qPCR L452R RT-qPCR	[WT] probe	Δ H69/V70 probe
[WT] probe	Omicron BA.2	Omicron BA.1
452R probe	Delta	Omicron BA.4/BA5

209

210 Validation was performed by pairwise comparison of results from the Variant-PCR with WGS using
211 the WGS consensus genome from the same samples as reference standard. We obtained valid RT-
212 qPCR results and a consensus genome sequence from each of the 745 selected SARS-CoV-2 PCR-
213 positive patient samples (Fig 3). In total, 339 patient samples were characterized with BA.1 infection

214 while 399 samples was identified as BA.2 by WGS analysis, showing a nearly even distribution
215 between BA.1 and BA.2 genomes. The Delta genome was found in the last seven patient samples.

216 The Δ H69/V70 mutation was detected by the degenerate Δ H69/V70 probe in 339 patient samples,
217 which correlated 100% with Omicron BA.1 WGS confirmed samples (Fig 3). Furthermore, 406
218 SARS-CoV-2 positive clinical samples had a WT signal being either of Delta or Omicron BA.2
219 origin. In the L452R RT-qPCR, seven samples were found positive for the 452R mutation
220 characteristic for the Delta variant in correlation with WGS results. The L452-WT sequence was
221 detected in 738 out of the 745 patient samples corresponding to the total consensus sequences
222 identified as Omicron by WGS, regardless of BA.1 and BA.2 sub-lineage identity. Thus, none of the
223 samples differed between the degenerate Δ H69/V70-WT RT-qPCR and WGS, demonstrating high
224 specificity (>99.9%) and high sensitivity (>99.9%) in large-scale as well as small-scale.

225 In summary, we developed a RT-qPCR system for rapid differentiation of Omicron BA.1 and BA.2
226 in large-scale, validated by comparison of RT-qPCR and WGS data from 745 patient samples
227 analyzed in parallel.

228 **Large-scale performance confirmation of BA.4 and BA.5 Omicron** 229 **variants**

230 The Danish national SARS-CoV-2 genomic surveillance system identified the first case of BA.4 in a
231 sample from 2nd of March, 2022. On 15th of April, 2022, the first case of BA.5 case was detected. At
232 this point in time, BA.2 accounted for more than 99% of all sequenced variants in Denmark (9). The
233 prevalence of BA.4 increased at a linear rate from 0.1% to 4.7% during the period from 11th of April
234 to 1st of June, 2022 with 327 identified BA.4 genomes in total. In contrast to BA.4, the prevalence of
235 BA.5 increased more rapidly and on 1st of June, 2022, 30.7% of all sequenced genomes from SARS-

236 CoV-2 positive throat samples were confirmed as BA.5 consensus sequences increasing the total
237 number to 1155 identified BA.5 cases (9). Since BA.5 clearly was heading to replace BA.2 as the
238 dominant SARS-CoV-2 lineage in Denmark, we investigated if our adapted RT-qPCR platform was
239 able to detect Omicron BA.4 and BA.5 sub-variants as a group, since this RT-qPCR *per se* will not
240 able to discriminate between them due to identical genomic sequences in the spike region.

241 Data obtained from WGS revealed that 92.5% of BA.4 consensus sequences (184/199) and 97.6% of
242 BA.5 consensus sequences (328/336) carried the Δ H69/V70 mutation. The prevalence of the mutation
243 452R is 93% and 98.8% in BA.4 and BA.5, respectively, which confirmed that both BA.4 and BA.5
244 carry both signature mutations. Based on alignment of unique sequences, 86 BA.4 and 53 BA.5,
245 respectively, the primers and probes in our L452R RT-qPCR had a complete match in all BA.4
246 sequences. Of the 53 analyzed BA.5 sequences, one showed an A-to-T mutation in the middle of the
247 L452R probe-binding region whereas primer-binding regions were found to be conserved. The BA.5
248 genomes had a perfect match to the primers and probe in the degenerate Δ H69/V70 RT-qPCR
249 whereas a single nucleotide mismatch, an A-to-G substitution located in the middle of the Δ H69/V70
250 forward primer (ACATTCAACTCGGGACTTGTCT), was observed in 10 of the 86 investigated
251 BA.4 sequences (12%), which may influence the performance of the RT-qPCR reaction.

252 Validation of the allelic Δ H69/V70-WT and the L452-WT discrimination RT-qPCRs were performed
253 on 66 SARS-CoV-2 positive patient samples collected from 24th to 26th of May, 2022 at Danish
254 community test facilities. Of these selected samples, 28 viral genomes were characterized as BA.4
255 and 38 as BA.5 by WGS. Results from our adapted Variant-PCR showed that both key mutations
256 were detected in combination in all selected samples as expected; *e.g.* all samples were infected with
257 a SARS-CoV-2 virus being Δ H69/V70-L452R double-positive in accordance with either a BA.4 or
258 BA.5 viral genotype (Fig 4).

259 Similar Ct-values were obtained in the E-Sarbeco RT-qPCR, indicating that all three RT-qPCRs
260 perform equally well with BA.4 and BA.5 variants, confirming high specificity of the degenerate
261 Δ H69/V70 probe for an Alpha VOC-like sequence, and providing evidence for high specificity of
262 this method in large-scale studies. Furthermore, we observed no pronounced differences in
263 amplification and detection of BA.4 viral genomes with a mismatch mutation in the sequence
264 recognized by the Δ H69/V70 forward primer compared to patient samples with a conserved sequence
265 (Fig 4).

266 In summary, our adapted Variant-PCR could rapidly detect Omicron BA.4 and BA.5 validated by
267 comparison of RT-qPCR and WGS data from 66 patient samples analyzed in parallel.

268 **Discussion**

269 Control of the pandemic caused by SARS-CoV-2 is challenged by the emergence of new variants,
270 emphasizing the need for rapid detection methods that complement WGS in order to support control
271 of transmission chains and assist public health response and decision-making. RT-qPCR is widely
272 deployed in diagnostic virology (15). In case of a public health emergency, laboratories can rely on
273 this robust technology to establish new diagnostic tests for screening within their routine services
274 before commercial assays become available. RT-qPCR strategies are of special interest in resource
275 lean countries to complement WGS, the golden standard for SARS-CoV-2 variant surveillance.
276 However, mutations in the targeting primer and probe sequences of new emerging variants can lead
277 to a failure of the existing RT-qPCRs.

278 Currently, most commercial kits for SARS-CoV-2 variant determination utilize a so-called S-gene
279 target failure phenomenon(16), where a detected variant positive for the *N* and *ORF1ab* genes, but
280 negative for *S* gene is interpreted as Omicron, due to the large number of mutations in the *S* gene of

281 this particular variant. The BA.1 sub-lineage showed S-gene target failure in RT-qPCRs due to the
282 presence of the Δ H69/V70 mutation, however, an S-gene target failure strategy may not be able to
283 detect the Omicron BA.2 lineage, which is currently the dominant SARS-CoV-2 virus circulating
284 worldwide, as BA.2 is missing this particular deletion.

285 Recently, several single one-step RT-qPCRs reported for the specific detection of Omicron in clinical
286 and environmental samples have been developed (17–19). As Omicron continues to spread and
287 evolve into several lineages and sub-lineages, these methods suffer, as they are not able to
288 differentiate between multiple Omicron sub-lineages, although they have been described as highly
289 specific and sensitive for Omicron.

290 The allelic discrimination RT-qPCR we propose using four probes targeting two signature mutations
291 in parallel has a very high accuracy enabling detection of known VOCs almost in real-time (within
292 24h) after sample collection. We provide evidence for simultaneous detection of the L452R mutation
293 and Δ H69/V70 deletion in spike protein in large-scale screening, using a degenerate probe to detect
294 and differentiate between circulating Omicron- and Delta variants. To the best of our knowledge, this
295 is the first RT-qPCR platform for specific detection and discrimination of Omicron sub-variants using
296 a degenerate probe. This strategy enables detection of a key deletion, Δ H69/V70, regardless of a
297 single nucleotide substitution or not, and hence, increases the robustness of the RT-qPCR. The
298 samples for large-scale performance evaluation were chosen to challenge the robustness of these RT-
299 qPCRs since lineage replacement is expected to occur during a pandemic transition period; the BA.1
300 sub-variant and its signature mutation, Δ H69/V70 with a single nucleotide substitution, was replaced
301 by BA.2 with a wildtype genotype at both targets, Δ H69/V70 and L452R. Later, the appearance of
302 BA.4 and BA.5 variants was observed in an increasing number of patient samples being positive for
303 both key mutations. In fact, Omicron being the predominant variant worldwide, negative results in

304 allelic discrimination RT-qPCR, but positive in other SARS-CoV-2 methods targeting conserved
305 elements of the SARS-CoV-2 genome such as E-Sarbeco, may indicate the emergence of novel
306 potential VOCs with S-gene mutations in target regions hindering recognition by the primers and/or
307 probes.

308 In summary, after adapting our Variant-PCR platform with a degenerate $\Delta H69/V70$ probe, we were
309 able to detect the four most common Omicron variants in circulation, BA.1, BA.2, BA.4 and BA.5,
310 and the Delta VOC, by combined analysis of two different signature mutations in parallel, $\Delta H69/V70$
311 and L452R, validated by a comparison of the RT-qPCR and WGS data. Furthermore, this method
312 enables us to differentiate between Omicron and Delta VOCs, between BA.1 and BA.2 sub-lineages,
313 and between BA.2 and emerging BA.4/BA.5 sub-lineages. If SARS-CoV-2 continues to evolve very
314 contagious VOCs with potential to escape humeral immune response, which may lead to a new wave
315 of COVID-19 infection, monitoring and screening might have to last for a prolonged period of time,
316 making the use of degenerate probes a useful strategy to adapt existing RT-qPCRs for SARS-CoV-2
317 detection.

318 **Acknowledgements**

319 We would like to extend our gratitude to Halenur Bayhan Ari, Kristina Finneisen and Caroline
320 Mølsted Benfeldt for their assistance and technical support.

321

322 **Figure legends**

323 **Fig 1. Detection of SARS-CoV-2 variants with the original $\Delta H69/V70$ probe based on the**
324 **SARS-CoV-2 alpha variant sequence. (A) Detection of SARS-CoV-2 variants with the original**

325 probe, including SARS-CoV-2 alpha variant as positive control and neg. SARS-CoV-2 patient
326 samples and a water control as negative controls. (B) Samples were tested as multiplex RT-qPCRs;
327 E-Sarbeco in parallel with the Δ H69/V70 RT-qPCR. Error bars in (A)-(B) indicate SEM for three
328 biological replicates.

329 **Fig 2. Detection of SARS-CoV-2 variants with a degenerate Δ H69/V70 probe based on the**
330 **SARS-CoV-2 BA.1 sequence.** (A) Detection of SARS-CoV-2 variants with a degenerate probe
331 targeting the Δ H69/V70. The SARS-CoV-2 Alpha- and BA.1 variants were included as positive
332 controls and neg. SARS-CoV-2 patient samples and a water control as negative controls. (B)
333 Detection of SARS-CoV-2 variants with the WT probe. SARS-CoV-2 WT, Delta and BA.2 variants
334 were included as positive controls and neg. SARS-CoV-2 patient samples and a water control as
335 negative controls.

336 **Fig 3. Detection of Δ H69/V70 and L452R mutations in BA.1 and BA.2**
337 (A) Allelic discrimination analysis to differentiate between the H69/V70 deletion and the WT
338 sequence. (B) Allelic discrimination analysis to differentiate between the 452R mutation and the
339 L452 WT sequence.

340 **Fig 4. Detection of Δ H69/V70 and L452R mutations in BA.4 and BA.5.**
341 (A) Allelic discrimination analysis to differentiate between the Δ H69/V70 mutation and the WT
342 sequence. (B) Allelic discrimination analysis to differentiate between the 452R mutation and the
343 L452 WT sequence.

344 **References**

- 345 1. World Health Organisation. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern
346 [Internet]. 2021. Available from: <https://www.who.int/news/item/26-11-2021-classification-of->

- 347 omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
- 348 2. outbreak.info. A standardized, open-source database of COVID-19 resources and epidemiology data
349 [Internet]. 2022. Available from: <https://outbreak.info/>
- 350 3. Majumdar S, Sarkar R. Mutational and phylogenetic analyses of the two lineages of the Omicron
351 variant. *J Med Virol*. 2022;94(5):1777–9.
- 352 4. Fonager J, Bennedbak M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular
353 epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November
354 2021 to 2 January 2022. *Eurosurveillance* [Internet]. 2022;27(10):1–7. Available from:
355 <http://dx.doi.org/10.2807/1560-7917.ES.2022.27.10.2200181>
- 356 5. Lyngse FP, Mortensen LH, Denwood MJ, Christiansen LE, Møller CH, Skov RL, et al. SARS-CoV-2
357 Omicron VOC Transmission in Danish Households. *medRxiv* [Internet]. 2021;2021.12.27.21268278.
358 Available from:
359 [https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1%0Ahttps://www.medrxiv.org/con](https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1%0Ahttps://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1.abstract)
360 [tent/10.1101/2021.12.27.21268278v1.abstract](https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1.abstract)
- 361 6. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but
362 incompletely escapes Pfizer BNT162b2 neutralization. *Nature*. 2022;602(7898):654–6.
- 363 7. Hu J, Peng P, Cao X, Wu K, Chen J, Wang K, et al. Increased immune escape of the new SARS-
364 CoV-2 variant of concern Omicron. *Cell Mol Immunol*. 2022;19(2):293–5.
- 365 8. Volz E et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking
366 epidemiological and genetic data. *medRxiv*. 2021;
- 367 9. covid19genomics.dk. Genomic overview of SARS-CoV-2 in Denmark [Internet]. 2022. Available
368 from: <https://www.covid19genomics.dk/statistics>
- 369 10. Cao Y et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. *Nature*.

- 370 2022;
- 371 11. Lyngse FP, Mølbak K, Skov RL, Christiansen LE, Mortensen LH, Albertsen M, et al. Increased
372 transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. *Nat Commun.*
373 2021;12(1):7251.
- 374 12. Spiess K, Gunalan V, Marving E, Nielsen SH, Karst SM, Danish T, et al. Rapid surveillance
375 platforms for key SARS-CoV-2 mutations in. *medRxiv.* 2021;
- 376 13. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel
377 coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* [Internet]. 2020;25(3). Available
378 from: <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
- 379 14. Candido KL, Eich CR, de Fariña LO, Kadowaki MK, da Conceição Silva JL, Maller A, et al. Spike
380 protein of SARS-CoV-2 variants: a brief review and practical implications. *Brazilian J Microbiol.*
381 2022;
- 382 15. Graham MAG, Allard SUAB, Asricha SHP, In BEL. Use of emerging testing technologies and
383 approaches for SARS-CoV-2: review of literature and global experience in an Australian context.
384 *Pathology.* 2021;53(6).
- 385 16. Erster O et al. Specific detection of SARS-CoV-2 B.1.1.529 (Omicron) variant by four RT-qPCR
386 differential assays. *medRxiv.* 2021;7(2):107–15.
- 387 17. Chassalevris T, Chaintoutis SC, Koureas M, Petala M, Moutou E, Beta C, et al. Wastewater
388 monitoring using a novel, cost-effective PCR-based method that rapidly captures the transition
389 patterns of SARS-CoV-2 variant prevalence (from Delta to Omicron) in the absence of conventional
390 surveillance evidence. *medRxiv* [Internet]. 2022;2022.01.28.21268186. Available from:
391 [https://www.medrxiv.org/content/10.1101/2022.01.28.21268186v1%0Ahttps://www.medrxiv.org/con](https://www.medrxiv.org/content/10.1101/2022.01.28.21268186v1%0Ahttps://www.medrxiv.org/content/10.1101/2022.01.28.21268186v1.abstract)
392 [tent/10.1101/2022.01.28.21268186v1.abstract](https://www.medrxiv.org/content/10.1101/2022.01.28.21268186v1.abstract)

- 393 18. Corbisier, Phillippe; Pertrillo, Mauro; Marchini, Antonio; Querci, Maddalena; Buttinger, Gerhard;
394 Bekliz, Meriem; Spiess, Katja; Polacek, Charlotta; Fomsgaard AGV den E. A qualitative RT-PCR
395 assay for the specific identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern. J
396 Clin Virol [Internet]. 2022;152(105191). Available from: <https://doi.org/10.1016/j.jcv.2022.105191>
- 397 19. Tung Phan, Stephanie Boes, Melissa McCullough, Jamie Gribschaw, Jane Marsh, Lee H. Harrison
398 AW. Development of a One-Step Qualitative RT-PCR Assay to Detect the SARS-CoV-2 Omicron
399 (B.1.1.529) Variant in Respiratory Specimens. J Clin Microbiol [Internet]. 2022;60(February):2–5.
400 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925893/>
- 401 20. Alfaro-Núñez A et al. SARS-CoV-2 RNA stability in dry swabs for longer storage and transport at
402 different temperatures. Transbound Emerg Dis. 2022;69:189–94.

403

404 **Supporting information**


405 **Supplementary Fig.1 SARS-CoV-2 Alpha variant standard sample detected by the original**
406 **and the degenerate probe.** (A) Dilution of the TWIST control standard (SARS-CoV-2 variant
407 Alpha) to a concentration of 10^{-3} copies/ μ l detected by the original and the degenerate probe
408 targeting the Δ H69/V70. (B) Dilution row of the TWIST control standard (SARS-CoV-2 variant
409 Alpha) detected by the original and the degenerate probe targeting the Δ H69/V70.

410

Figure 1

A

original H69/70 Δ probe



B

E-Sarbeco PCR





Figure 2

A

Degenerate H69/70 Δ probe



B

WT H69/70 probe




Figure 3






Figure 4



Supplementary Figure 1

A



B

